Logo

Transgenomic MX-ICP Liquid Biopsy Tests

Mar 10, 2016

Transgenomic has launched its MX-ICP CRC Analysis and MX-ICP Melanoma Analysis. These two new liquid biopsy cancer panels are based on the company's Multiplexed ICE COLD-PCR (MX-ICP) technology.

  • MX-ICP CRC Analysis is a comprehensive panel that tests for the relevant mutations in a range of actionable genes that are among the most common gene mutations in colorectal cancer. These include KRAS and NRAS exons 2, 3, and 4; BRAF exon 15; PIK3CA exons 9 and 20; and EGFR exon 12 (S492R).

  • MX-ICP Melanoma Analysis is a panel that tests for BRAF exon 15 and NRAS exon 2 and 3 mutations, which have been identified in approximately 50 percent to 75 percent of malignant melanoma tumors, and are associated with differential response to treatment.

The panels are available for clinical use through Transgenomic's Oncology CLIA laboratory in Omaha, Nebraska.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.